IMMUNOHISTOCHEMISTRY PANEL (3-IHC) at Test Zone Diagnostic Center

Understanding the IMMUNOHISTOCHEMISTRY PANEL (3-IHC) at Test Zone Diagnostic Center

The IMMUNOHISTOCHEMISTRY PANEL (3-IHC) at Test Zone Diagnostic Center is a highly specialized, state-of-the-art pathology investigation used to identify specific diagnostic markers within tissue samples. Immunohistochemistry (IHC) combines anatomical, immunological, and biochemical techniques to image discrete components in tissues. This is achieved through the interaction of target antigens with specific antibodies tagged with a visible label, such as a fluorescent dye or an enzyme. When standard Hematoxylin and Eosin (H&E) staining under a microscope is insufficient to provide a definitive diagnosis, pathologists utilize a 3-IHC panel to analyze three distinct cellular proteins. This targeted approach helps differentiate between benign and malignant tumors, determine the primary origin of metastatic cancers, and classify complex neoplasms with high precision.

At Test Zone Diagnostic Center in Peshawar, Pakistan, this advanced diagnostic tool plays a pivotal role in modern oncology and personalized medicine. By evaluating three carefully selected antibodies, our consultant pathologists can pinpoint the exact lineage of abnormal cells. The technology relies on highly specific monoclonal and polyclonal antibodies that bind to target epitopes on the cell surface, within the cytoplasm, or inside the nucleus. This antigen-antibody binding is then visualized using advanced chromogenic detection systems, resulting in a distinct color change that can be analyzed under a high-resolution light microscope. The diagnostic value of a 3-IHC panel is immense, as it directly influences therapeutic decisions, prognostic assessments, and patient management strategies. It provides clinicians with the molecular-level evidence required to design targeted therapies, such as hormone treatments for breast cancer or immunotherapy for specific carcinomas.

Clinical Procedure: What to Expect

Patient Preparation

Because the IMMUNOHISTOCHEMISTRY PANEL (3-IHC) is performed on tissue samples that have already been extracted from the body, there is no direct physical preparation required from the patient on the day of the test. However, ensuring the accuracy of the results requires meticulous preparation regarding sample submission:

• Tissue Block Submission: Patients must submit the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block, commonly referred to as the “biopsy block” or “paraffin block,” along with the corresponding glass slides from the initial biopsy or surgical resection.
• Previous Pathology Reports: It is mandatory to provide the original histopathology report (H&E stained report) and all relevant clinical history, imaging reports (such as CT, MRI, or ultrasound scans), and the referring physician's prescription.
• Sample Integrity: Ensure that the tissue block has been processed and fixed using standard 10% neutral buffered formalin. Improper fixation can lead to antigen degradation and false-negative results.
• No Fasting Required: Since no direct blood draw or invasive procedure is performed on the patient during this phase, fasting or medication adjustments are not necessary unless specifically instructed by your physician for a concurrent procedure.

During the Procedure

The technical execution of the IMMUNOHISTOCHEMISTRY PANEL (3-IHC) at Test Zone Diagnostic Center involves a series of highly controlled laboratory steps performed by specialized histotechnologists and evaluated by consultant pathologists:

• Sectioning: The submitted paraffin block is mounted on a microtome, and ultra-thin sections (typically 3 to 5 microns thick) are cut and mounted onto specially coated glass slides to prevent tissue detachment.
• Deparaffinization and Rehydration: The tissue sections are heated and treated with solvents like xylene to remove the paraffin wax, followed by graded alcohols to rehydrate the tissue.
• Antigen Retrieval: Formalin fixation causes cross-linking of proteins, which can mask target antigens. The laboratory utilizes Heat-Induced Epitope Retrieval (HIER) or Proteolytic-Induced Epitope Retrieval (PIER) to break these cross-links and expose the target proteins to the antibodies.
• Antibody Incubation: The tissue sections are incubated with three specific primary antibodies selected based on the clinical indication (e.g., ER, PR, and HER2 for breast tissue). After washing, secondary antibodies conjugated with enzymes (such as horseradish peroxidase) are applied.
• Chromogen Application: A chromogenic substrate (usually diaminobenzidine or DAB) is added, which reacts with the enzyme to produce a visible, permanent colored precipitate (usually brown) at the site of antigen-antibody binding.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to provide contrast to the cell nuclei, dehydrated, and sealed with a coverslip.
• Microscopic Evaluation: A Consultant Pathologist examines the slides under a high-power microscope to assess the intensity, localization (nuclear, cytoplasmic, or membranous), and percentage of cellular staining.

When is an IMMUNOHISTOCHEMISTRY PANEL (3-IHC) Performed?

Differentiating Benign from Malignant Lesions

One of the primary indications for ordering a 3-IHC panel is when standard microscopic examination cannot clearly distinguish between a benign, reactive process and a malignant neoplasm. For instance, in prostate biopsies, differentiating between atypical adenomatous hyperplasia and prostatic adenocarcinoma can be challenging. A 3-IHC panel utilizing markers like p63, High Molecular Weight Cytokeratin (HMWCK), and AMACR (Alpha-Methylacyl-CoA Racemase) can clearly outline the presence or absence of the basal cell layer, confirming or ruling out malignancy with absolute clinical certainty.

Identifying the Primary Site of Metastatic Tumors

When a patient presents with metastatic cancer where the primary tumor site is unknown, a 3-IHC panel is crucial. For example, if a biopsy of a liver or lung lesion reveals metastatic adenocarcinoma, pathologists use a panel of lineage-specific markers such as Cytokeratin 7 (CK7), Cytokeratin 20 (CK20), and Thyroid Transcription Factor-1 (TTF-1) or CDX2. The specific staining pattern (e.g., CK7 positive, CK20 negative, and TTF-1 positive) helps pinpoint the primary origin of the cancer, such as the lung, gastrointestinal tract, or breast, which is vital for selecting the correct systemic therapy.

Subtyping Lymphomas and Hematological Malignancies

Lymphomas comprise a highly diverse group of cancers with vastly different treatment protocols and prognoses. When a lymph node biopsy shows atypical lymphoid proliferation, a 3-IHC panel is often the first step in classification. By selecting three key markers, such as CD20 (to identify B-cells), CD3 (to identify T-cells), and Ki-67 (to assess cellular proliferation rate), pathologists can rapidly categorize the lymphoma into B-cell or T-cell lineage and estimate its aggressiveness, guiding the oncologist toward the most effective chemotherapy regimen.

Determining Prognostic and Predictive Markers in Breast Cancer

In breast oncology, the IMMUNOHISTOCHEMISTRY PANEL (3-IHC) is standard practice for every newly diagnosed invasive breast carcinoma. The panel typically evaluates Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2). The expression levels of these three proteins act as both prognostic indicators (predicting the course of the disease) and predictive markers (determining if the patient will respond to hormone therapies like tamoxifen or targeted therapies like trastuzumab).

Classifying Undifferentiated and Poorly Differentiated Tumors

When tumors are highly aggressive, they often lose their normal cellular characteristics, appearing as “undifferentiated” or “anaplastic” cells under a microscope. In such cases, it is impossible to tell if the tumor is a carcinoma, sarcoma, melanoma, or lymphoma. A 3-IHC panel utilizing broad lineage markers like Pan-Cytokeratin (for epithelial tumors), Vimentin (for mesenchymal tumors), and S100 or SOX10 (for melanocytic tumors) provides the essential clues needed to categorize the tumor and initiate appropriate clinical management.

What Does an IMMUNOHISTOCHEMISTRY PANEL (3-IHC) Detect?

The IMMUNOHISTOCHEMISTRY PANEL (3-IHC) is designed to detect the presence, localization, and concentration of specific cellular proteins. Depending on the clinical scenario, the panel can detect and evaluate:

• Estrogen Receptor (ER): Nuclear staining indicating hormone-sensitive breast cancer cells.
• Progesterone Receptor (PR): Nuclear staining that works in tandem with ER to guide endocrine therapy.
• HER2/neu: Membranous staining indicating overexpression of the HER2 oncogene in breast or gastric cancers.
• Ki-67: A nuclear marker representing the active proliferative phase of cells, indicating tumor growth rate.
• p63: A nuclear marker highlighting basal cells, useful in distinguishing invasive breast or prostate cancers from in situ lesions.
• Cytokeratin 7 (CK7): An intermediate filament protein expressed in epithelial cells of the lung, breast, and upper GI tract.
• Cytokeratin 20 (CK20): Expressed primarily in epithelial cells of the colon, rectum, and Merkel cells.
• CD20: A cell-surface marker specific to B-lymphocytes, crucial for diagnosing B-cell lymphomas.
• CD3: A T-cell co-receptor marker used to identify T-lymphocytes and T-cell malignancies.
• CD30: Expressed on Reed-Sternberg cells in Hodgkin lymphoma and anaplastic large cell lymphomas.
• TTF-1 (Thyroid Transcription Factor-1): A nuclear marker positive in primary lung adenocarcinomas and thyroid cancers.
• CDX2: A nuclear transcription factor specific to intestinal epithelial cells, indicating colorectal origin.
• S100 Protein: A cytoplasmic and nuclear marker highly sensitive for melanoma, neural crest tumors, and schwannomas.
• Melan-A (MART-1): A specific melanocytic differentiation antigen used to confirm metastatic melanoma.
• Synaptophysin: A glycoprotein found in synaptic vesicles, indicating neuroendocrine differentiation.
• Chromogranin A: An acidic glycoprotein present in secretory granules of neuroendocrine cells.
• PSA (Prostate Specific Antigen): Confirms the prostatic origin of metastatic adenocarcinoma in male patients.
• Desmin: An intermediate filament protein specific to smooth and skeletal muscle differentiation.
• Vimentin: A major structural protein of mesenchymal cells, positive in sarcomas and some carcinomas.
• Calretinin: A calcium-binding protein expressed in mesothelial cells, helping diagnose mesothelioma.
• WT1 (Wilms Tumor 1): Useful in diagnosing ovarian serous carcinomas and pediatric renal tumors.
• E-cadherin: A cell adhesion molecule used to differentiate ductal (positive) from lobular (negative) breast carcinomas.
• GATA3: A transcription factor highly sensitive for breast and urothelial carcinomas.
• PAX8: A nuclear marker positive in renal, thyroid, and Müllerian (ovarian/endometrial) tumors.
• CD45 (Leukocyte Common Antigen): Confirms the hematopoietic nature of a tumor, distinguishing lymphoma from carcinoma.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for pathology results can be an anxious time for patients and their families. Because immunohistochemistry is a highly complex, multi-step process requiring precise chemical reactions, tissue processing, and expert microscopic analysis, the turnaround time for an IMMUNOHISTOCHEMISTRY PANEL (3-IHC) is typically 5 to 7 working days. This timeline ensures that every step, from antigen retrieval to final pathologist review, is executed under strict quality control protocols.

Once the report is finalized and signed off by our Consultant Pathologist, patients are immediately notified via SMS. Test Zone Diagnostic Center offers convenient digital access to diagnostic reports. Patients can download their verified, high-resolution PDF reports directly from our secure online portal or mobile application. Physical copies of the reports, along with the submitted tissue blocks and slides, can also be collected from our main diagnostic facility in Peshawar. We recommend keeping these blocks and slides in a cool, dry place, as they may be required for future reference or second opinions.

IMMUNOHISTOCHEMISTRY PANEL (3-IHC) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Estrogen Receptor (ER)	Negative (No nuclear staining in normal non-target tissues)	Positive nuclear staining (Indicates hormone-sensitive breast carcinoma)
HER2/neu Expression	Negative or Score 0/1+ (Normal cell membrane expression)	Score 3+ Positive (Membranous overexpression indicating HER2-positive cancer)
Ki-67 Proliferation Index	Low proliferation (Typically < 5% in normal resting tissues)	High proliferation (> 20% to 90% indicating rapidly dividing, aggressive tumor cells)
Cytokeratin 7 / 20 Profile	Depends on tissue origin (e.g., Lung: CK7+/CK20-)	Abnormal coordinate expression (e.g., CK7-/CK20+ in metastatic lung lesion, suggesting colorectal origin)
CD20 / CD3 Lymphoid Markers	Balanced distribution of B and T cells in lymphoid tissue	Monoclonal expansion (e.g., diffuse sheets of CD20+ cells indicating B-cell Lymphoma)
p63 Basal Cell Marker	Intact, continuous basal cell layer in breast ducts/prostate glands	Complete loss of p63 staining (Indicates invasive carcinoma)
Synaptophysin / Chromogranin	Negative in non-neuroendocrine tissues	Diffuse cytoplasmic positivity (Confirms neuroendocrine tumor/carcinoma)
S100 / SOX10 Melanocytic Markers	Negative in epithelial tissues	Strong positive staining (Confirms melanoma or neural crest origin)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for IMMUNOHISTOCHEMISTRY PANEL (3-IHC)?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified, board-certified Consultant Pathologists with extensive experience in oncopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic journey.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to international standards of quality control and assurance in histopathology.
• Professional Reporting: Our reports are detailed, comprehensive, and structured to provide oncologists with the exact molecular data required for treatment planning.
• Modern Diagnostic Approach: We utilize advanced automated staining platforms that minimize human error and ensure highly reproducible staining patterns.
• Comfortable Environment: Our diagnostic facility in Peshawar is designed to provide a welcoming, clean, and professional environment for all patients and visitors.
• Convenient Location: Located centrally in Peshawar, our center is easily accessible to patients from across Khyber Pakhtunkhwa.
• Commitment to Accurate Diagnosis: We understand the critical impact of pathology reports on cancer treatment, and we are dedicated to delivering absolute diagnostic accuracy.